文献速递泌尿生殖介入CTMR

影像引导经皮冷冻消融治疗肾肿瘤的结局:区域中心即时及3年和5年结局

Outcomes of Renal Tumors Treated by Image-Guided Percutaneous Cryoablation: Immediate and 3- and 5-Year Outcomes at a Regional Center.
PubMed 文献 · AJR Am J Roentgenol · 2020-04-14

本研究在区域介入肿瘤中心评估影像引导经皮冷冻消融治疗临床T1期(cT1)活检证实的肾细胞癌(RCC)的即时及3年和5年结局。共纳入180例患者185个cT1 RCC病灶,技术成功率为98.9%(183/185),主要并发症率(Clavien-Dindo分级≥III级)为2.2%(4/185),首次随访发现残留未消融肿瘤为2.2%(4/183)。3年和5年估计局部肿瘤无进展生存率分别为98.3%和94.9%;未发生远处转移或RCC相关死亡;术前平均eGFR为72.4 ± 18.5 mL/min/1.73 m2,术后及1年、2年随访与术前无统计学显著差异(p > 0.05)。

要点

  • 影像引导经皮冷冻消融治疗cT1 RCC的技术成功率达98.9%(183/185)。
  • 主要并发症率(Clavien-Dindo≥III级)为2.2%(4/185)。
  • 3年和5年估计局部肿瘤无进展生存率分别为98.3%和94.9%。

关键影像表现/征象

  • 共180例患者185个独立cT1 RCC病灶,其中cT1a病灶168个(90.8%)、cT1b病灶17个(9.2%),平均病灶大小28.5 mm(范围11-58 mm)。
  • 技术成功在185例中的183例(98.9%)实现。
  • 首次随访扫描发现残留未消融肿瘤在183个肿瘤中的4个(2.2%)。

诊断标准与关键数值

  • 技术成功率为98.9%(183/185)。
  • 主要并发症率(Clavien-Dindo分级≥III级)为2.2%(4/185)。
  • 残留未消融肿瘤率为2.2%(4/183)。
  • 3年估计局部肿瘤无进展生存率为98.3%,5年为94.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to evaluate the immediate and 3- and 5-year outcomes of patients with clinical stage T1 (cT1) biopsy-proven renal cell carcinoma (RCC) treated by image-guided percutaneous cryoablation at a regional interventional oncology center. MATERIALS AND METHODS. A prospectively maintained local interventional radiology database identified patients with cT1 RCC lesions that were treated by percutaneous cryoablation. Technical success, procedural complications (graded using the Clavien-Dindo classification system), and the residual unablated tumor rate were collated. Local tumor progression-free survival was estimated using Kaplan-Meier estimates. RESULTS. A total of 180 patients with 185 separate cT1 RCC lesions were identified. Mean patient age was 68.4 years (range, 34.1-88.9 years) and 52 patients (28.9%) were women. There were 168 (90.8%) and 17 (9.2%) cT1a and cT1b lesions, respectively, with a mean lesion size of 28.5 mm (range, 11-58 mm). Technical success was achieved in 183 of 185 (98.9%) patients. The major complication rate (Clavien-Dindo classification ≥ grade III) was 2.2% (four out of 185). Residual unablated tumor on the first follow-up scan was identified in four of 183 tumors (2.2%). Estimated local tumor progression-free survival at 3 and 5 years was 98.3% and 94.9%, respectively. No distant metastases or deaths attributable to RCC occurred. Mean estimated glomerular filtration rate (eGFR) before the procedure was 72.4 ± 18.5 (SD) mL/min/1.73 m2 and this was not statistically significantly different after the procedure (69.7 ± 18.8 mL/min/1.73 m2), at 1 year (70.7 ± 16.4 mL/min/1.73 m2), or at 2 years (69.8 ± 18.9 mL/min/1.73 m2) (p > 0.05). CONCLUSION. These data add to the accumulating evidence that image-guided cryoablation is an efficacious treatment for selected cT1 RCC with a low complication rate and ro bust 3- and 5-year outcomes.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Lim E, Kumar S, Seager M, et al. Outcomes of Renal Tumors Treated by Image-Guided Percutaneous Cryoablation: Immediate and 3- and 5-Year Outcomes at a Regional Center. AJR Am J Roentgenol. 2020. PMID: 32286877. doi:10.2214/AJR.19.22213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。